

## **FUJIFILM Medical Systems U.S.A., Inc. Strengthens Healthcare Portfolio with Addition of In Vitro Diagnostics Solutions**

*FUJIFILM Wako Diagnostics U.S.A. Corporation will become part of FUJIFILM Medical Systems U.S.A., Inc.*

**Lexington, Mass., August 17, 2020** – FUJIFILM Medical Systems U.S.A., Inc. announced today that effective October 1, 2020, it will add In Vitro Diagnostics (IVD) to its portfolio of healthcare solutions with the integration of FUJIFILM Wako Diagnostics U.S.A. Corporation, a provider of IVD and life science products. The integration will enhance FUJIFILM Medical Systems U.S.A. Inc.'s portfolio of diagnostic solutions for its healthcare customers through the addition of IVD clinical lab reagents and biomarkers.

“With an established portfolio of diagnostic imaging solutions to enable treatment planning, diagnosis and healthcare IT, we look forward to expanding our solutions to include IVD,” said Jun Higuchi, president and chief executive officer, FUJIFILM Medical Systems U.S.A., Inc. “The addition of IVD to our diagnostic portfolio will enable us to provide clinicians with tools to assess risks of disease development through our biomarkers and our existing diagnostic imaging solutions.”

FUJIFILM Wako Diagnostics has an established portfolio of biomarkers to assess the risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease. Its IVD portfolio of solutions also includes IVD reagents and systems focused on areas including disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes.

The new IVD group will be led by Hidetoshi (Henry) Izawa, vice president of modality solutions and clinical affairs, FUJIFILM Medical Systems U.S.A., Inc. As part of his current role, Mr. Izawa oversees digital radiography, computed radiography and women's health groups. Previously, he was responsible for radiology, IVD and endoscopy for FUJIFILM France, and was the Head of Modality for Europe.

“This integration will enable us to leverage our expanded resources at FUJIFILM Medical Systems U.S.A., Inc. to offer enhanced clinical support and customer service to IVD customers,” said Henry Izawa, vice president of modality solutions and clinical affairs, FUJIFILM Medical Systems U.S.A., Inc. “We are thrilled to welcome the talented men and women of FUJIFILM Wako Diagnostics U.S.A. Corporation to our group to accelerate new innovations in IVD.”

To learn more about Fujifilm's comprehensive healthcare solutions, visit [www.fujifilmhealthcare.com](http://www.fujifilmhealthcare.com).

### **About Fujifilm**

[FUJIFILM Medical Systems U.S.A., Inc.](http://www.fujifilmhealthcare.com) is a leading provider of unrivaled diagnostic imaging products and medical informatics solutions that meet the evolving needs of healthcare facilities today and into the future. Medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, as well as technologically advanced flexible and surgical endoscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse® Enterprise Imaging portfolio, which includes the [TeraMedica Division of Fujifilm](http://www.fujifilmhealthcare.com). FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit [www.fujifilmhealthcare.com](http://www.fujifilmhealthcare.com).

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical,

electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of \$21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: [www.fujifilmholdings.com](http://www.fujifilmholdings.com).

**Contact:**

Fujifilm

Christine Jackman

christine.jackman@fujifilm.com

(914) 261-4959